Estybon (rigosertib) - Traws Pharma
pevonedistat (MLN4924) - Takeda
sabatolimab (MBG453) - Novartis
mitoxantrone - Generic mfg.
Rytelo (imetelstat) - Geron
vadastuximab talirine (SGN-CD33A) - Pfizer
Tecentriq (atezolizumab) - Roche
Tibsovo (ivosidenib) - Servier
azacitidine - Generic mfg.
decitabine - Generic mfg.
magrolimab (ONO-7913) - Ono Pharma, Gilead
Idhifa (enasidenib) - BMS, Servier
emavusertib (CA-4948) - Curis, Dr. Reddy’s
Recentin (cediranib) - AstraZeneca
entospletinib (GS-9973) - Ignota Labs
Keytruda (pembrolizumab) - Merck (MSD)
onvansertib (PCM-075) - Cardiff Oncology
Beleodaq (belinostat) - Aurobindo, Assertio
flotetuzumab (MGD006) - MacroGenics
eprenetapopt (APR-246) - Aprea
Tasigna (nilotinib) - Novartis, Inhibikase
Farydak (panobinostat) - Secura Bio
alvocidib (DSP-2033) - Sumitomo Pharma
Rezlidhia (olutasidenib) - Rigel
https://ashpublications.org/blood/article/146/Supplement%201/6934/555460/Efficacy-of-novel-agents-in-the-treatment-of-acute
 
Hafiz Muhammad Hannan Javed 1; Moazzam Shahzad 2; Utsav Joshi 2; Muhammad Kashif Amin 3; Muhammaf Fareed Khalid 4; Zaker Schwabkey 5
 
Dec 5, 2025
 
Next